Drug intelligence / Profile preview

MRA 003 US

Development stage: Unknown
Lead developer: National Institute of Arthritis and Musculoskeletal and Skin Diseases
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

MRA 003 US is an investigational humanized monoclonal antibody designed to block the action of interleukin-6 (IL-6) by targeting its receptor. IL-6 is a cytokine that plays a crucial role in inflammation and antibody production, making its blockade a potential therapeutic strategy for autoimmune diseases. The drug has been investigated in clinical trials for conditions such as Systemic Lupus Erythematosus.

Targets

IL-6R (Interleukin-6 receptor subunit alpha)

Beyond the preview

Go deeper on MRA 003 US.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MRA 003 US.

Explore the full profile